Low serum neurofilament light chain values identify optimal responders to dimethyl fumarate in multiple sclerosis treatment
Abstract Serum neurofilament light chains (sNfL) are biomarkers of disease activity in multiple sclerosis (MS), but their value to predict response to treatment, and their association with patient immunological profile, need to be further explored. We studied 80 relapsing–remitting MS patients initi...
Guardado en:
Autores principales: | Paulette Esperanza Walo-Delgado, Susana Sainz de la Maza, Noelia Villarrubia, Enric Monreal, Silvia Medina, Mercedes Espiño, José Ignacio Fernández-Velasco, Eulalia Rodríguez-Martín, Ernesto Roldán, Daniel Lourido, Alfonso Muriel, Jaime Masjuan-Vallejo, Lucienne Costa-Frossard, Luisa María Villar |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/8c728d8ae2de49b8accdc64e3ffacaf7 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Dimethyl fumarate is an allosteric covalent inhibitor of the p90 ribosomal S6 kinases
por: Jacob Lauwring Andersen, et al.
Publicado: (2018) -
Therapeutic efficacy of dimethyl fumarate in relapsing-remitting multiple sclerosis associates with ROS pathway in monocytes
por: Karl E. Carlström, et al.
Publicado: (2019) -
Dimethyl fumarate prevents acute lung injury related cognitive impairment potentially via reducing inflammation
por: Xiaowei Wang, et al.
Publicado: (2021) -
IL-17+ CD8+ T cell suppression by dimethyl fumarate associates with clinical response in multiple sclerosis
por: Christina Lückel, et al.
Publicado: (2019) -
Dimethyl Fumarate Alleviates NLRP3 Inflammasome Activation in Microglia and Sickness Behavior in LPS-Challenged Mice
por: Bora Tastan, et al.
Publicado: (2021)